Introduction
Well differentiated thyroid cancer (WDTC) is rising in incidence in the USA and across the world over the past three decades (1) (2) (3) (4) (5) . Unlike most human malignancies, WDTC has high cure rates when managed appropriately (6) (7) (8) . Our understanding of the biology of this common disease and the impact of treatment on patient outcome has evolved over the past century. Over this time period, management of thyroid cancer has evolved from a wide spectrum of treatment approaches to a more standardized evidence based approach, due to improved understanding of the biological behavior of this cancer, and supported by national and international guidelines (9) (10) (11) . Surgery remains the cornerstone of management of thyroid cancer with post-operative radioactive iodine administered as adjuvant treatment in selected cases based on risk of recurrence and risk of disease specific mortality. The objective of our study is to present the changing trends in the incidence, presentation, management and outcomes of WDTC within our institution over the past 8 decades.
Patients and Methods
Following approval by the Institutional Review Board, 2797 patients who had thyroid surgery for WDTC between 1932 and 2005 at Memorial Sloan Kettering Cancer Center, New York, were identified from our institutional database. Data collection was carried out over two separate time periods, with reports based on the initial cohort (1932-1985, n=987 ) published separately from the subsequent group (1986-2005, n=1810 ). Both cohorts were combined to produce the data presented in this manuscript. Patients with anaplastic, poorly differentiated and medullary carcinoma, as well as those who were selected as not suitable for surgery were excluded from these studies. Data collected included patient demographics, surgical details including extent of thyroid surgery, histopathological diagnosis at the time of treatment and pTNM status. Data on adjuvant radioactive iodine remnant ablation (RRA) was also collected. In-depth analysis of recurrence data have been presented previously (12) . In this manuscript we present data on 10 year disease specific survival (DSS). Mode of death was determined from case notes and death certificates where available, and cross checked against the social security index for all patients. Patients who were known to have died of disease were coded as cause specific death. Those who died of other causes were censored at the time of death for DSS analysis. Patients who died during follow up, and no cause could be confirmed were considered to have died of disease if there was evidence of disease at last follow up, in order not to underestimate the effect of disease. Our institutional approach to the management of WDTC involves risk stratification using the previously reported GAMES criteria (Table 1) (13) . These criteria, consider patient and tumor factors in risk stratification. This classification was designed to predict the risk of death from WDTC, rather than the risk of recurrence. Patients are considered at low risk if under the age of 45 years, and high risk if over 45 years. Tumors with more aggressive histology, which are larger than 4cms, and/or have extrathyroid extension or have distant metastases are considered high risk tumors. In contrast, well differentiated tumors that are less than 4 cms, and are intrathyroidal, and have no evidence of distant metastases are considered low risk tumors. Thus, patients above 45 years age with high risk tumors are considered in the high risk group. Patients under the age of 45, with low risk tumors are included in the low risk group. All others are included in the intermediate risk group. i.e. young patients with high risk tumors or older patients with low risk tumors. Our philosophy of management has been to advocate ipsilateral lobectomy in low risk patients with a unifocal intraglandular tumor, without any detectable abnormality in the opposite lobe. Assessment of the contralateral lobe is by intra-operative examination. Nowadays, this is supplemented with preoperative ultrasound. These patients do not receive RRA therapy. In the high risk group, a total thyroidectomy or even more extensive resection and post-operative RRA is recommended. Surgical resection of all clinically apparent disease is the mainstay of treatment and to this end extracapsular total thyroidectomy is performed with resection of strap muscles, recurrent nerve and even laryngotracheal or esophageal structures as indicated to ensure macroscopic surgical clearance. For intermediate risk cases, an individualized treatment decision is made based on discussion between the surgeon, endocrinologist and patient and is mainly based on tumor factors. This approach to risk stratification and treatment was adopted during the time period of the initial cohort and has remained our standard of care for subsequent decades. In terms of management of the neck, we do not perform routine elective central or lateral compartment neck dissection. The cervical nodal basins are examined clinically, ultrasonographically (in more recent years) and intra-operatively. For a clinically positive neck, with palpable node in the lateral compartment, an anatomically comprehensive, and oncologically effective selective neck dissection ( lymph nodes at levels II,III,IV and V) is carried out. If suspicious nodes are identified during surgery of the primary tumor, frozen section is used to confirm metastatic disease, and appropriate neck dissection is carried out depending on the location of the metastatic nodes. Central compartment dissection is performed only if suspicious nodes are noted during thyroidectomy and confirmed by frozen section. 
Results
Patient, tumor and treatment characteristics of the group as a whole and stratified by the date of initial surgical management by decade are shown in Figure 1 ). The median age of the whole group was 45 years (range 4-94 years). In comparison with the earlier cohort, patients managed post 1985 were more likely to be over the age of 45 years (53% versus 44%, p<0.001).
The percentage of women in the cohort increased from 68% to 72% in the more recent cohort (p=0.026), and the percentage of tumors classified as papillary carcinoma also increased from 78% to 92%, p<0.001. An increase in early stage tumors was observed during the study with pT1 lesions increasing from 19% in the early cohort to 48% in the latter cohort. For pT4 tumors, representing locally advanced tumors, we saw no increase in incidence with 8% in the early cohort and 7% in the latter cohort. Throughout the decades there has been a rise in the percentage of papillary carcinomas presenting with our institution. In the earlier cohort, around 75% of WDTC were classified a papillary carcinoma, which rose to 86% between 1986-1995 and 94% between 1996-2005. This corresponded with a fall in the percentage of follicular carcinomas from 18% to 3% over the same time period. In part, this change may be explained by changes in the definition of follicular carcinoma, with some patients now being classified as follicular variant of papillary carcinoma.
The percentage of patients with pathologically positive neck nodes fell from 48% to 33% (p<0.001). The incidence of patients with distant metastasis at presentation was similar (4% in the early versus 3% in the later cohort, p=0.262). The rising age of patients resulted in an increased percentage of intermediate risk cases in the later cohort, and a reduced number of low risk cases. However, the number of cases considered high risk remained relatively constant (Table 4a) . Trends in treatment revealed that patients in the later cohort were less likely to have thyroid lobectomy (29% versus 72%, p<0.001), with a corresponding increase in rates of total thyroidectomy. There was also a significant change in the use of RRA, (Table 3) . This improvement in outcome is most marked in the high risk group (Table 4b) . Since the introduction of risk group stratification, and individualized treatment protocols based on such an approach (around the 1970s) DSS has not changed significantly. 10 year DSS rates were below 90% in the cohort managed prior to the 1970s, which rose to >95% thereafter (p<0.001).
Analysis of factors predictive of poorer outcome for the whole group confirmed non-papillary histology, age over 45 years, the presence of distant metastasis, evidence of extrathyroid extension and size over 4cms as independent predictors on multivariate analysis (GAMES) (14) . In contrast, the presence of lymph node metastases was not predictive of DSS ( Table 5) .
Discussion
Over the past century there has been a gradual change in the management of thyroid cancer. A number of major centers have published the results of institutional series spanning many decades (15, 16) . The incidence and presenting features of this common disease have undergone significant changes in recent times. It is now recognized that the incidence of papillary thyroid carcinoma is rising at a faster rate than any other malignancy (17) . The reasons proposed for this are contentious. There is no doubt that enhanced imaging has resulted in increased rates of detection, particularly of cancers less than 1cm in size (microcarcinomas) (3, 17) . However, there has also been an increase in tumors greater than 4-6cm, suggesting that the increasing incidence may be a true increase caused by other yet unknown factors (18) . Thyroid cancer is recognized as being more common in females. However, recent reports suggest the incidence in women may be increasing at a higher rate than in males (4). The incidence has also been reported to be increasing at a faster rate in older patients (17) . Early reports of deaths from WDTC suggested that less than total thyroidectomy procedures resulted in less favorable oncological outcomes, and that all gross disease should be removed as part of the initial surgical procedure (19) (20) (21) . Debate about the required extent of initial surgical therapy continues, with an understanding that thyroid lobectomy is a safe and effective option in low risk, unifocal, intraglandular thyroid cancers (9-11, 22) The management of the contralateral lobe in low risk cases has been long debated with evidence supporting both lobectomy alone (23, 24) and total thyroidectomy (25, 26) . In the absence of prospective randomized controlled trials, this debate is unlikely to be resolved. In high risk cases, the place of total thyroidectomy is widely accepted.
Over the past 8 decades at MSKCC there has been an increase in the rate of total thyroidectomy (Figure 2) . High resolution ultrasound imaging in the pre-operative investigation of patients with WDTC has increased the number of contralateral thyroid nodules identified preoperatively. This, previously considered occult disease, now results in total thyroidectomy rather than thyroid lobectomy being adopted, even in low risk patients. Surgical practice has therefore gone full circle, with an initial move away from total thyroidectomy to thyroid lobectomy for selected low risk caseswith now a move back towards total thyroidectomy to excise previously occult contralateral nodular disease, regardless of its histological status. The role of RRA also remains unclear in certain situations. For low risk patients, little benefit has been demonstrated(27, 28), whereas in high risk cases the benefits are more certain(28). The therapeutic efficacy of RRA in the management of WDTC has led to a large increase in its use, even in low risk patients, at many major centers across the US(29). Our results over the past 73 years reflect the changes described above, with an increasing number of cases managed within our institution over the past 8 decades (Figure 1) . Along with this volume increase, we have also observed a trend towards an older patient group (94% versus 53%, p<0.001), with a higher percentage of women represented in recent years (72% versus 68%, p=0.026) ( Table 2 ). These trends may be due to a change in referral patterns with increased access to ultrasound in both primary care and obstetrics and gynecology practice.
Analysis of survival of the whole group confirms our earlier reports that non-papillary histology, age over 45 years, the presence of distant metastases, extrathyroid extension, and size over 4cms are predictive of poorer DSS. The results of analysis of both patient and tumor related factors underscore the importance of risk stratification, to allow for individualization in the management of WDTC ( Table 5 ).
In terms of histopathological subtypes of WDTC, papillary thyroid carcinoma remains the most prevalent, with an increasing percentage in recent years (92% versus 78%, p<0.001). There has also been a reduction in the incidence of follicular carcinoma, from 16% to 5% (p<0.001). This is likely due to the recognition that many primary lesions previously described as follicular carcinoma are now categorized as follicular variant of papillary carcinoma. A further change in histological reporting has resulted in the recognition of poorly differentiated thyroid carcinoma. Towards the end of our study this was recognized as a separate histological entity, and was reported separately. Although we found a relatively constant rate of pT4 disease presented throughout the decades, some more recent pT4 cancers may have been recognized as poorly differentiated and therefore excluded from this analysis. In keeping with other reports, we also noted a significant increase in the number of microcarcinomas (<1cm). pT1 disease comprised 48% of the recent cohort of patients compared to 19% of the earlier cohort, p<0.001. Interestingly, nodal disease has decreased in prevalence, from 48% to 33% (p<0.001). This may be due to the increase in early T stage tumors that we now see. It may also be due to a change in neck dissection policy since our risk stratification system was introduced, with neck dissection only being carried out for clinically palpable neck disease in the past , and more recently for radiographically detected lymph node metastases. The percentage of patients presenting with evidence of distant metastases has remained constant at less than 5%, suggesting that the percentage of patients presenting with aggressive, high risk disease that is likely to affect survival has not changed dramatically over the 7 decade period. With regards to our risk stratification system (GAMES), we observed a shift of low risk cases to the intermediate risk group category (Table 4a) . This is as a result of the older patient age at presentation, despite the increases in low risk tumors. Only 25% of patients in the earlier cohort underwent total thyroidectomy versus 68% in the recent cohort. In our institution, even older patients with intraglandular WDTC are selected for thyroid lobectomy. Therefore a change in overall risk stratification should have a limited effect on rates of total thyroidectomy. This change in practice therefore is likely to be multifactorial in etiology. Along with the change in risk groups, the introduction of preoperative ultrasound over this time period has resulted in more occult nodular disease in the contralateral lobe being detected. As a consequence, there has been an increase in the number of total thyroidectomies. In addition, the increased number of total thyroidectomies may also be accounted for by several international guidelines now recommending total thyroidectomy for intra-thyroid lesions over 1.5cm (9-11). Post-operative adjuvant RRA was rarely used in the early part of this study, but has become a part of therapy for 44% of cases in recent times (Figure 2) . Over the past few years we have become increasingly aware of the side effects of RRA as well as the risk of second primaries. As a result, we now carefully consider the risk versus benefit ratio before recommending treatment with RRA.
DSS for patients managed during this study has increased significantly from below 90% to over 95% in the later years ( Table 3) . This improvement is in keeping with other series and demonstrates the excellent outcomes that most patients with WDTC now experience. Careful scrutiny of these figures however demonstrates that these improvements were largely achieved prior to the mid-1970s (Table 4b) . It was at this time that evidence to support the surgical techniques now routinely employed was starting to appear. This is with particular reference to abandoning the practice of subtotal or near total thyroidectomyand instituting the practice of routine "extracapsular" total thyroidectomy Around this time the understanding of risk stratification was improving with several investigators presenting their own method for predicting outcome in patients with WDTC (27, 30, 31). More recently, despite the increase in the rates of total thyroidectomy and RRA, no significant improvement in DSS has been observed for a cancer which already had excellent outcomes (Figure 2) . These figures are affected by the changing trends in presentation. An increased number of intermediate risk cases are now seen (Table 4a) . Analysis on a risk group specific level show improvement in each time period studies (Table 4b ) although overall, improved survival was more marked from the mid 1970s.
Over the past 8 decades in our institution, the incidence, presentation and management of WDTC has changed considerably. Older patients with earlier stage disease present an increasing workload for our department. It is likely that the incidence of WDTC will continue to rise in the short to medium term at least. Already excellent outcomes are unlikely to be significantly improved with an ever more aggressive approach to treatment. Opportunities to improve standards of care include identifying patient groups most likely to benefit from aggressive contemporary management and at the same time developing new therapeutic strategies. Efforts must also include attempts to identify those patients who will benefit from less invasive treatment, which would reduce the potential lifelong impact that complications of therapy can have, whilst maintaining oncological outcomes and allowing focusing of resources on those patients most likely to benefit. Our efforts in clinical care in future need to be focused to reducing mortality from thyroid cancer, and in the discovery of new treatment modalities, that will create a positive impact on patients with distant metastatic disease, for whom we have little to offer at this time. Percentage of patients undergoing total thyroidectomy, receiving RRA and disease specific survival by decade
